<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00916201</url>
  </required_header>
  <id_info>
    <org_study_id>EICAS</org_study_id>
    <nct_id>NCT00916201</nct_id>
  </id_info>
  <brief_title>Evaluation Study of New Compounds With Potential Use in Schizophrenia</brief_title>
  <acronym>EICAS</acronym>
  <official_title>Evaluation of Potential Central Glucoregulatory Compounds to Treat/Ameliorate the Symptoms of Schizophrenia: a Proof-of-concept Study in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Institute of Mental Health, Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Max-Planck Institute for Metabolism Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central Institute of Mental Health, Mannheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Different compounds that might modify the glucose regulation in the central nervous system&#xD;
      will be evaluated in healthy volunteers. Several examinations will be performed in order to&#xD;
      get a detailed plan how these substances might work.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical assessment with several psychopathological scores for self-assessment and peer evaluation (BPRS, PANSS, SIPS, CGI, MADRS, HAM-A, SCL-90-R)</measure>
    <time_frame>Seven days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory assessment (routine testing, &quot;-omics&quot;, genetic analyses, endocannabinoid levels)</measure>
    <time_frame>Seven days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostics of the cerebrospinal fluid</measure>
    <time_frame>Seven days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>fMRI scan of the brain</measure>
    <time_frame>Seven days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regular evaluating of the subject's condition and ability to continue the study by CGI</measure>
    <time_frame>Seven days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regular laboratory testing and ECG</measure>
    <time_frame>Seven days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scales for the assessment of adverse events (UKU, SCL- 90-R)</measure>
    <time_frame>Seven days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Numbers of) SAE and AE</measure>
    <time_frame>Seven days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Intranasal Insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal administered insulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cannabidiol CR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cannabidiol is the main non psychoactive compound of the Cannabis sativa plant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>URB597</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>URB597 is a selective inhibitor of the Fatty acid amide hydrolase enzyme.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>URB597</intervention_name>
    <description>10 mg / d for 5 days, orally</description>
    <arm_group_label>URB597</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intranasal Insulin</intervention_name>
    <description>160 IU / d for 5 days, intranasal</description>
    <arm_group_label>Intranasal Insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol CR</intervention_name>
    <description>320 mg / d for 5 days, orally</description>
    <arm_group_label>Cannabidiol CR</arm_group_label>
    <other_name>Arvisol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers&#xD;
&#xD;
          -  Informed consent given by the subject&#xD;
&#xD;
          -  Both, female and male subjects may participate&#xD;
&#xD;
          -  Age between 18 and 65 years&#xD;
&#xD;
          -  Negative drug-screening at the time of screening&#xD;
&#xD;
          -  In female participants in fertile age, reliable contraception, which means&#xD;
             contraception's pearl-index is equal or smaller than 1.&#xD;
&#xD;
          -  Non-Smoker&#xD;
&#xD;
          -  Body Mass Index between 18 and 40.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lack of accountability&#xD;
&#xD;
          -  Any current psychiatric disorder through the Structured Clinical Interview for DSM-IV&#xD;
             (SCID) at the time of screening&#xD;
&#xD;
          -  Any known psychiatric or neurological illness in the participant's history.&#xD;
&#xD;
          -  Known family history concerning psychiatric disorders&#xD;
&#xD;
          -  Relevant use of cannabis (which is defined on the present state of knowledge as at the&#xD;
             most five times lifetime-consumption and no consumption for at least one year)&#xD;
&#xD;
          -  Pregnancy or lactation phase in female at the time of screening&#xD;
&#xD;
          -  Severe physical (internal) or neurological illness, especially cardiovascular, renal,&#xD;
             advanced respiratory, haematological or endocrinological failures or infectious&#xD;
             diseases (acute hepatitis A, B or C or HIV) assessed at the time of the screening by&#xD;
             the subject's history, clinical examination and laboratory testing, at the discretion&#xD;
             of the investigator&#xD;
&#xD;
          -  Consumption of any illegal drugs (except cannabis in history, see above)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>F. Markus Leweke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Institute of Mental Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>F. Markus Leweke, MD</last_name>
    <phone>+49 621 1703</phone>
    <phone_ext>2321</phone_ext>
    <email>leweke@cimh.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cathrin Rohleder, PhD</last_name>
    <phone>+49 621 1703</phone>
    <phone_ext>2333</phone_ext>
    <email>rohleder@cimh.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dep. of Psychiatry and Psychotherapy, Central Institute of Mental Health</name>
      <address>
        <city>Mannheim</city>
        <state>BW</state>
        <zip>68159</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>F. Markus Leweke, MD</last_name>
      <phone>+49 621 1703</phone>
      <phone_ext>2321</phone_ext>
      <email>leweke@cimh.de</email>
    </contact>
    <contact_backup>
      <last_name>Cathrin Rohleder, PhD</last_name>
      <phone>+49 621 1703</phone>
      <phone_ext>2333</phone_ext>
      <email>rohleder@cimh.de</email>
    </contact_backup>
    <investigator>
      <last_name>J. Malte Bumb, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cathrin Rohleder, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Till van der List, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juliane K. Mueller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frank Enning, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 5, 2009</study_first_submitted>
  <study_first_submitted_qc>June 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2009</study_first_posted>
  <last_update_submitted>August 12, 2019</last_update_submitted>
  <last_update_submitted_qc>August 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Institute of Mental Health, Mannheim</investigator_affiliation>
    <investigator_full_name>F Markus Leweke</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cannabidiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

